Business

Contraceptive Devices Market Outlook 2022-2027, Industry Demand, Share, Forecast

Contraceptive Devices Market

Contraceptive Devices Market Overview:

The latest report published by IMARC Group, titled, “Contraceptive Devices Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027″, offers a comprehensive analysis of the industry, which comprises insights on the Contraceptive Devices Market Outlook. The report also includes competitor and regional analysis, and contemporary advancements in the market. The global contraceptive devices market reached US$ 12.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 18.7 Billion by 2027, exhibiting a growth rate (CAGR) of 6.96% during 2022-2027. Contraceptive devices refer to birth control tools used to prevent pregnancies and sexually transmitted diseases (STDs). These devices are customized for both male and female users and comprise spermicides to chemically neutralize sperms. Condoms, diaphragms, sponges, cervical caps, vaginal rings, subdermal implants and intrauterine devices (IUD) are some of the commonly used contraceptive devices.

Global Contraceptive Devices Market Trends:

The rising prevalence of STDs, including chlamydia, hepatitis B, gonorrhea, trichomoniasis, HIV/AIDS, represents one of the significant factors strengthening the growth of the contraceptive devices market across the globe. Moreover, the growing consciousness among individuals about the available alternatives for minimizing unexpected pregnancies is catalyzing the demand for contraceptive devices. Furthermore, leading manufacturers are investing in research and development (R&D) activities to develop product variants with higher efficacy and minimal side effects. This, in confluence with the increasing inclination toward delayed pregnancies and rising healthcare expenditures of individuals, is anticipated to fuel the market growth.

Competitive Landscape with Key Players:

  • Allergan Plc
  • Bayer Healthcare
  • Church & Dwight Co. Inc.
  • Cooper Surgical Inc.
  • Merck & Co.
  • Mylan Laboratories
  • Pfizer Inc.
  • Reckitt Benckiser
  • Teva Pharmaceutical Industries Ltd.
  • The Female Health Company

Key Market Segmentation:

Device Type:

  • Condoms
  • Diaphragms
  • Cervical Caps
  • Sponges
  • Vaginal Rings
  • IUDs
  • Others

End User:

  • Male
  • Female

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others

Application:

  • Household
  • Commercial
  • Others

Region:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key Highlights of the Report:
  • Market Performance (2016-2021)
  • Market Outlook (2022-2027)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Report Coverage:

Report FeaturesDetails
Base Year of the Analysis2021
Historical Period2016-2021
Forecast Period2022-2027
UnitsUS$ Billion
Segment CoverageDevice Type, End User, Distribution Channel, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries CoveredUnited States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies CoveredAllergan plc, Bayer AG, Church & Dwight Co., Inc., CooperSurgical Inc., Merck & Co., Mylan Inc., Pfizer Inc., Reckitt Benckiser Group plc, Teva Pharmaceutical Industries Ltd., and The Female Health Company
Customization Scope10% Free Customization
Report Price and Purchase OptionSingle User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support10-12 Weeks
Delivery FormatPDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Leave a Reply

Your email address will not be published. Required fields are marked *